Zhengwen Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhengwen Liu has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Qunying Han
Department of Infectious Diseases, First Affiliated Hospital of Xi'an Jiaotong University, Xi' an 710061, Shaanxi, China
4 shared publicationsNa Li
Department of Infectious Diseases, First Affiliated Hospital of Xi'an Jiaotong University, Xi' an 710061, Shaanxi, China
3 shared publicationsJinghong Chen
Institute of Endemic Diseases, School of Medicine, Xi'an Jiaotong University, Key Laboratory of Environment and Genes related to Diseases, Ministry of Education, Xi'an, Shaanxi, People's Republic of China
2 shared publicationsNi Zhang
2 shared publicationsQun-Ying Han
2 shared publicationsYi Lv
Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China
2 shared publications
Latest Publications
- Open Access
- 2 May 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (28) , 46020-46033
Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection
Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection
- 2 May 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (28) , 46020-46033
Open AccessCirculating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection
Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection
- 17 February 2016
- Published by Wiley in Journal of Medical Virology
- Vol. 88 (9) , 1552-1559
Differential association of STAT3 and HK‐II expression in hepatitis B virus‐ and hepatitis C virus‐related hepatocellular carcinoma
STAT3 and hexokinase II (HK-II) are involved in viral infection and carcinogenesis of various cancers including hepatocellular carcinoma (HCC). The roles of STAT3 and HK-II in hepatitis B virus (HBV)- and hepatitis C virus (HCV)-related HCC remain largely unclear. This study examined STAT3 and HK-II expression in HBV- and HCV-related HCC, HBV-related liver fibrosis, and normal control liver by using tissue microarray and immunohistochemical method. Results showed that STAT3 expression in HBV-related HCC, HCV-related HCC, and HBV-related liver fibrosis was significantly higher than in control liver (P < 0.001, P = 0.016, and P = 0.005, respectively) and had no significant differences between these three diseased liver tissues. The HK-II expression in HBV-related HCC was significantly higher than that in HCV-related HCC, HBV-related liver fibrosis, and control liver (P = 0.007, P = 0.029, and P = 0.008, respectively) but had no significant elevation in and no significant differences between HCV-related HCC, HBV-related liver fibrosis, and control liver. The HK-II expression was significantly correlated to STAT3 expression in HBV-related HCC (P = 0.022), but no correlation was observed in HCV-related HCC, HBV-related liver fibrosis, and control liver. In conclusion, STAT3 expression is upregulated in both HBV- and HCV-related HCC, while HK-II is predominantly upregulated and correlated to STAT3 in HBV-related HCC. These differential expression and association may suggest the distinct roles of STAT3 and HK-II in hepatocarcinogenesis of HBV and HCV infection. Studies are needed to confirm the relationship of STAT3 and HK-II and to examine the underlying mechanisms. J. Med. Virol. 88:1552–1559, 2016.
- 17 February 2016
- Published by Wiley in Journal of Medical Virology
- Vol. 88 (9) , 1552-1559
Differential association of STAT3 and HK‐II expression in hepatitis B virus‐ and hepatitis C virus‐related hepatocellular carcinoma
STAT3 and hexokinase II (HK-II) are involved in viral infection and carcinogenesis of various cancers including hepatocellular carcinoma (HCC). The roles of STAT3 and HK-II in hepatitis B virus (HBV)- and hepatitis C virus (HCV)-related HCC remain largely unclear. This study examined STAT3 and HK-II expression in HBV- and HCV-related HCC, HBV-related liver fibrosis, and normal control liver by using tissue microarray and immunohistochemical method. Results showed that STAT3 expression in HBV-related HCC, HCV-related HCC, and HBV-related liver fibrosis was significantly higher than in control liver (P < 0.001, P = 0.016, and P = 0.005, respectively) and had no significant differences between these three diseased liver tissues. The HK-II expression in HBV-related HCC was significantly higher than that in HCV-related HCC, HBV-related liver fibrosis, and control liver (P = 0.007, P = 0.029, and P = 0.008, respectively) but had no significant elevation in and no significant differences between HCV-related HCC, HBV-related liver fibrosis, and control liver. The HK-II expression was significantly correlated to STAT3 expression in HBV-related HCC (P = 0.022), but no correlation was observed in HCV-related HCC, HBV-related liver fibrosis, and control liver. In conclusion, STAT3 expression is upregulated in both HBV- and HCV-related HCC, while HK-II is predominantly upregulated and correlated to STAT3 in HBV-related HCC. These differential expression and association may suggest the distinct roles of STAT3 and HK-II in hepatocarcinogenesis of HBV and HCV infection. Studies are needed to confirm the relationship of STAT3 and HK-II and to examine the underlying mechanisms. J. Med. Virol. 88:1552–1559, 2016.
- 15 September 2010
- Published by Elsevier in Human Immunology
- Vol. 71 (12) , 1209-1213
Association of polymorphisms of programmed cell death–1 gene with chronic hepatitis B virus infection
- 15 September 2010
- Published by Elsevier in Human Immunology
- Vol. 71 (12) , 1209-1213
Association of polymorphisms of programmed cell death–1 gene with chronic hepatitis B virus infection
- 22 August 2006
- Published by Wiley in Journal of Medical Virology
- Vol. 78 (10) , 1289-1295
Association of genetic polymorphism of low‐density lipoprotein receptor with chronic viral hepatitis C infection in Han Chinese
To study the association between the Ava II polymorphism at the low‐density lipoprotein receptor (LDL‐R) gene exon 13 locus and chronic hepatitis C virus (HCV) infection in the Han Chinese, 84 chronic HCV‐infected patients without anti‐viral treatment, and 72 healthy blood donors were studied. Polymerase chain reaction combined with restriction fragment length polymorphism (PCR‐RFLP) was used to detect the Ava II polymorphism at the LDL‐R gene exon 13 locus. The comparisons of genotype distribution and allele frequency between chronic HCV‐infected patients and healthy controls showed statistically significant differences (P = 0.045 and P = 0.036, respectively). Additionally, the minor allele frequency (MAF) C in the healthy controls was higher than that in the chronic HCV‐infected patients group. There was no significant difference (P = 0.130) when the genotype distribution was compared between chronic HCV‐infected patients with HCV viremia and those without HCV viremia. However, the comparisons of allele frequency between the two groups showed a statistically significant difference (P = 0.047), and the MAF C in HCV RNA negative group was significantly higher than that in HCV RNA positive group. There were no significant differences in genotype distribution and allele frequency of the Ava II restriction site at the LDL‐R gene exon 13 locus between patients with chronic HCV infection and those with HCV‐associated cirrhosis as well as between patients with normal serum alanine aminotransferase (ALT) and those with abnormal ALT levels. These results suggest that the Han Chinese have Ava II polymorphism at the LDL‐R gene exon 13 locus. The Ava II polymorphism at the LDL‐R gene exon 13 locus showed a statistically significant difference between chronic HCV‐infected patients and healthy controls, indicating a significant contribution of the Ava II polymorphism in susceptibility to HCV infection in these patients. The MAF C in HCV RNA negative group was higher than that in HCV RNA positive group, suggesting that the Ava II polymorphism might also be associated with viremia in patients with HCV infection. J. Med. Virol. 78:1289–1295, 2006.
- 22 August 2006
- Published by Wiley in Journal of Medical Virology
- Vol. 78 (10) , 1289-1295
Association of genetic polymorphism of low‐density lipoprotein receptor with chronic viral hepatitis C infection in Han Chinese
To study the association between the Ava II polymorphism at the low‐density lipoprotein receptor (LDL‐R) gene exon 13 locus and chronic hepatitis C virus (HCV) infection in the Han Chinese, 84 chronic HCV‐infected patients without anti‐viral treatment, and 72 healthy blood donors were studied. Polymerase chain reaction combined with restriction fragment length polymorphism (PCR‐RFLP) was used to detect the Ava II polymorphism at the LDL‐R gene exon 13 locus. The comparisons of genotype distribution and allele frequency between chronic HCV‐infected patients and healthy controls showed statistically significant differences (P = 0.045 and P = 0.036, respectively). Additionally, the minor allele frequency (MAF) C in the healthy controls was higher than that in the chronic HCV‐infected patients group. There was no significant difference (P = 0.130) when the genotype distribution was compared between chronic HCV‐infected patients with HCV viremia and those without HCV viremia. However, the comparisons of allele frequency between the two groups showed a statistically significant difference (P = 0.047), and the MAF C in HCV RNA negative group was significantly higher than that in HCV RNA positive group. There were no significant differences in genotype distribution and allele frequency of the Ava II restriction site at the LDL‐R gene exon 13 locus between patients with chronic HCV infection and those with HCV‐associated cirrhosis as well as between patients with normal serum alanine aminotransferase (ALT) and those with abnormal ALT levels. These results suggest that the Han Chinese have Ava II polymorphism at the LDL‐R gene exon 13 locus. The Ava II polymorphism at the LDL‐R gene exon 13 locus showed a statistically significant difference between chronic HCV‐infected patients and healthy controls, indicating a significant contribution of the Ava II polymorphism in susceptibility to HCV infection in these patients. The MAF C in HCV RNA negative group was higher than that in HCV RNA positive group, suggesting that the Ava II polymorphism might also be associated with viremia in patients with HCV infection. J. Med. Virol. 78:1289–1295, 2006.
- Open Access
- 1 January 2005
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 11 (22) , 3357-3362
Correlation of serum leptin levels with anthropometric and metabolic parameters and biochemical liver function in Chinese patients with chronic hepatitis C virus infection
Correlation of serum leptin levels with anthropometric and metabolic parameters and biochemical liver function in Chinese patients with chronic hepatitis C virus infection
- 1 January 2005
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 11 (22) , 3357-3362
Open AccessCorrelation of serum leptin levels with anthropometric and metabolic parameters and biochemical liver function in Chinese patients with chronic hepatitis C virus infection
Correlation of serum leptin levels with anthropometric and metabolic parameters and biochemical liver function in Chinese patients with chronic hepatitis C virus infection
- Open Access
- 1 January 2004
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 10 (7) , 972-976
Sequential changes of serum ferritin levels and their clinical significance in lamivudine-treated patients with chronic viral hepatitis B
AIM: To study the sequential changes of serum ferritin levels in lamivudine-treated patients with chronic viral hepatitis B and the clinical implications. METHODS: Thirty-eight patients with chronic viral hepatitis B were prospectively studied during their treatment with lamivudine. Each patient received 100 mg oral lamivudine daily for 12 mo, and was observed and tested for blood biochemistry and hepatitis B virus (HBV) DNA levels and serum ferritin levels at baseline and at 3, 6 and 12 mo during the treatment. Serum HBV DNA levels were quantitatively determined using fluorescent quantitative polymerase chain reaction (FQ-PCR), and serum ferritin levels were measured by radioimmunoassay. The sequential changes of serum ferritin levels and their relationships with virological, serological and biochemical responses in the patients were analyzed. RESULTS: All the patients had a baseline HBV DNA level higher than 1 × 107 copies/L as determined by FQ-PCR and positive HBsAg and HBeAg and abnormal ALT levels. At the end of the 12-mo treatment, 19 of the 38(50.00%) patients had undetectable serum HBV DNA levels by FQ-PCR, and 12(31.58%) became negative for serum HBeAg and 10(26.32%) had seroconversion from HBeAg to HBeAb. Nineteen out of the 38(50.00%) patients had biochemically normal ALT levels after 12-mo lamivudine treatment. Sequential determination showed that lamivudine treatment significantly reduced ferritin levels in chronic hepatitis B patients. When the patients were divided into different groups according to their post-treatment virological, serological and biochemical responses for analysis of the sequential changes of ferritin levels, it was found that the decrease of ferritin levels in HBV DNA-negative group was significantly more obvious than that in HBV DNA-positive group at 6 mo during the treatment (P = 0.013). Consecutive comparisons showed that ferritin levels at 3 mo of treatment were obviously decreased as compared with the baseline levels (P < 0.05) in HBeAg-negative group, and the decrease of serum ferritin levels in patients with normalized ALT was more significant than that in patients with abnormal ALT at the end of the 12-mo treatment (P = 0.048). CONCLUSION: Lamivudine treatment can reduce the serum ferritin levels in chronic viral hepatitis B patients and decreases of ferritin levels can be more significant in patients exhibiting virological, serological and biochemical responses, indicating that dynamic observation of serum ferritin levels in patients with chronic viral hepatitis B during lamivudine treatment might be helpful for monitoring and predicting patients’ responses to the therapy.
- 1 January 2004
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 10 (7) , 972-976
Open AccessSequential changes of serum ferritin levels and their clinical significance in lamivudine-treated patients with chronic viral hepatitis B
AIM: To study the sequential changes of serum ferritin levels in lamivudine-treated patients with chronic viral hepatitis B and the clinical implications. METHODS: Thirty-eight patients with chronic viral hepatitis B were prospectively studied during their treatment with lamivudine. Each patient received 100 mg oral lamivudine daily for 12 mo, and was observed and tested for blood biochemistry and hepatitis B virus (HBV) DNA levels and serum ferritin levels at baseline and at 3, 6 and 12 mo during the treatment. Serum HBV DNA levels were quantitatively determined using fluorescent quantitative polymerase chain reaction (FQ-PCR), and serum ferritin levels were measured by radioimmunoassay. The sequential changes of serum ferritin levels and their relationships with virological, serological and biochemical responses in the patients were analyzed. RESULTS: All the patients had a baseline HBV DNA level higher than 1 × 107 copies/L as determined by FQ-PCR and positive HBsAg and HBeAg and abnormal ALT levels. At the end of the 12-mo treatment, 19 of the 38(50.00%) patients had undetectable serum HBV DNA levels by FQ-PCR, and 12(31.58%) became negative for serum HBeAg and 10(26.32%) had seroconversion from HBeAg to HBeAb. Nineteen out of the 38(50.00%) patients had biochemically normal ALT levels after 12-mo lamivudine treatment. Sequential determination showed that lamivudine treatment significantly reduced ferritin levels in chronic hepatitis B patients. When the patients were divided into different groups according to their post-treatment virological, serological and biochemical responses for analysis of the sequential changes of ferritin levels, it was found that the decrease of ferritin levels in HBV DNA-negative group was significantly more obvious than that in HBV DNA-positive group at 6 mo during the treatment (P = 0.013). Consecutive comparisons showed that ferritin levels at 3 mo of treatment were obviously decreased as compared with the baseline levels (P < 0.05) in HBeAg-negative group, and the decrease of serum ferritin levels in patients with normalized ALT was more significant than that in patients with abnormal ALT at the end of the 12-mo treatment (P = 0.048). CONCLUSION: Lamivudine treatment can reduce the serum ferritin levels in chronic viral hepatitis B patients and decreases of ferritin levels can be more significant in patients exhibiting virological, serological and biochemical responses, indicating that dynamic observation of serum ferritin levels in patients with chronic viral hepatitis B during lamivudine treatment might be helpful for monitoring and predicting patients’ responses to the therapy.